Technology
Health
Pharmaceutical

Sienna Biopharmaceuticals

$2.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-4.33%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell SNNA and other stocks, options, ETFs, and crypto commission-free!

About

Sienna Biopharmaceuticals, Inc. Common Stock, also called Sienna Biopharmaceuticals, is a clinical-stage biopharmaceutical company that focuses on the discovery, clinical development, and commercialization of aesthetics and medical dermatology. Read More Its products include Topical by Design platform for patients with inflammatory skin diseases and other dermatologic and aesthetic conditions through SNA-120, SNA-125, and SNA-001. The company was founded by Todd Harris and Frederick C. Beddingfield III on July 27, 2010 and is headquartered in Westlake Village, CA.

Employees
58
Headquarters
Westlake Village, California
Founded
2010
Market Cap
53.01M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
176.93K
High Today
$2.57
Low Today
$2.42
Open Price
$2.56
Volume
54.17K
52 Week High
$21.53
52 Week Low
$2.05

Collections

Technology
Health
Pharmaceutical
Medical
2017 IPO
US
North America

News

Markets InsiderMar 21

Sienna Biopharmaceuticals Promotes Alexander Azoy to Chief Financial Officer and Appoints Sean Andrews to Leadership Team as Vice President, Investor Relations

-- John W. Smither Departing for Personal Reasons WESTLAKE VILLAGE, Calif., March 21, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced the promotion of Alexander Azoy to Chief Financial Officer (CFO). Mr. Azoy, who has served as Sienna’s Corporate Controller since December 2017, will succeed John W. Smither, who has resigned for personal reasons, effective April 1, 2019. “We are delighted to announce Alex’s promotion to C...

61
Seeking AlphaMar 14

Sienna Biopharmaceuticals reports Q4 results

Sienna Biopharmaceuticals (NASDAQ:SNNA): Q4 GAAP EPS of -$0.93. Cash and cash equivalents of $69.8M including net proceeds from February 2019 follow-on public offering. Press Release...

188
Simply Wall StMar 8

Investors Who Bought Sienna Biopharmaceuticals Shares A Year Ago Are Now Down 87%

The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But it should be a priority to avoid stomach churning catastrophes, wherever possible. It must have been painful to be a Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) shareholder over the last year, since the stock price plummeted 87% in that time. That’d be enough to make even the strongest stomachs churn. We wouldn’t rush to judgement on Sienna Biopharmaceuticals because we don’t have a long ...

18

Earnings

-$6.50
-$4.52
-$2.54
-$0.56
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.83 per share
Actual
Available Mar 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.